Nanostart AG (NASRY: OTC Link) | Nanostart investment BioMers: Growth financing round successfully concluded


Nanostart investment BioMers: Growth financing round successfully concluded

Nov 08, 2011

OTC Disclosure News Service

Frankfurt, Germany / Singapore –

  • Financing of SGD 6 million
  • Holding of Nanostart Singapore-fund remains constant
  • Funding to be used for commercial expansion

– November 8, 2011 – Singapore Nanostart (OTCQX: NASRY) investment BioMers has successfully concluded a round of financing for around SGD 6 million (approximately €3.5 million). Its new investors include a further venture capital fund and several private investors. Nanostart is investing pro rata in this financing round and thereby keeping Nanostart Singapore Early Stage Venture Fund’s share in BioMers largely constant at about 24%.

Andreas Kröll, Managing Director of Nanostart Asia, commented: “Investors had a very keen interest in acquiring a stake in BioMers, which confirms the enormous potential the company has for decisively shaping the market for esthetic dental correction.”

The new funding is intended for the further expansion of BioMers. This includes building a new production facility in Singapore, expanding the sales and marketing team and sales and marketing support activities focusing on Singapore, the US and selected countries in Europe.

About Nanostart:
Nanostart AG (OTCQX:NASRY) headquartered in the German financial capital of Frankfurt, is a leading nanotechnology investment company, with portfolio companies spanning the globe from Silicon Valley to Singapore. The company provides venture capital financing for nanotechnology companies in various growth phases with a focus on innovation-driven industries of the future such as cleantech, life sciences and IT/electronics. Through its subsidiary Nanostart Asia and the venture capital fund in Singapore, Nanostart is proud to be the investment partner of the Singaporean government. For further information, please visit

About BioMers:
BioMers is a medical device company that has developednovel polymer composite products for numerous biomedical applications. The company’s flagship product is the SimpliClear™ braces system, which is the world’s first and only aesthetic solution for all types of orthodontic treatments. This translucent, almost invisible braces system is customized to each patient, providing faster and better results. Established in 2005, BioMersis a spin-off company from the National University of Singapore, where the technology was invented. BioMers has received seed funding from NUS Enterprise,venture capital funding from the Nanostart Singapore Early Stage Venture Fund, and grants from government agencies, including SPRING Singapore and the Economic Development Board. For more information, please visit


This notice constitutes neither an offer to sell nor a solicitation of offers to purchase or subscribe to securities. There will be no public offering of securities of Nanostart AG in conjunction with the existing listing of its shares in the “Entry Standard” segment of the regulated unofficial market (Freiverkehr) on the Frankfurt Stock Exchange. This notice does not constitute a securities prospectus. Neither this notice nor the information contained within is intended for direct or indirect distribution within Canada, Australia or Japan.

Media contact:
Nanostart AG
Dr. Hans Joachim Duerr
Head of Corporate Communications
Goethestrasse 26-28
D-60313 Frankfurt am Main
phone: +49 (0)69-21 93 96 111
fax: +49 (0)69-21 93 96 150


The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Leave a Reply